

Special Issue

New Insights into Antimicrobial Discovery

Message from the Guest Editors

Antibiotics have revolutionized modern medicine, making it possible to treat otherwise deadly bacterial infections. Misuse of antibiotics has allowed the selection of resistant strains that do not respond to conventional treatments. Antibiotic resistance is a leading cause of morbidity and mortality, causing millions of deaths worldwide each year. To this end, the scientific community is conducting continuous research to discover new antibacterial agents with alternative mechanisms of action and pharmacological targets. This Special Issue covers all aspects of antimicrobial discovery, including nanomaterials, natural and synthetic compounds, repurposed drugs, and modifications of existing drugs for the treatment of multidrug-resistant infections. We invite researchers to contribute with original research and review articles.

Guest Editors

Dr. Veronica Folliero

Department of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy

Dr. Gianluigi Franci

Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana"/DIPMED, University of Salerno, Baronissi, 84081 Salerno, Italy

Deadline for manuscript submissions

closed (30 September 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.2
Indexed in PubMed



mdpi.com/si/125858

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.2
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)